



Contribution ID: 60

Type: **Invited**

## **Augmented and individualized radionuclide treatment (advances in PRRT / PRLT with a clinical focus on PSMA targeted radioligand therapy)**

*Tuesday 30 April 2019 10:30 (30 minutes)*

With translation of new radioligands into clinical theragnostic practice, the therapeutic branch of nuclear medicine has gained fundamental momentum. The agonist-to-antagonist change in paradigm for different peptide receptor targeting systems is another current issue of major relevance. PSMA-targeted approaches are being discussed as role model treatment approach. Understanding the mechanism and specific issues of PSMA-targeted PRLT, as well as potential risk factors for unfavorable course of disease under therapy, is helpful to escalate PRLT when needed. Indications for PRLT and arguments for earlier application will be covered, as well as contraindications and pseudo-contraindications. Augmentation methods for PRLT including comedication and potential maintenance therapy in PRLT responders are matters of clinical concern. Also toxicity issues of Lu177 and Ac225 based PSMA-targeted PRLT, covering the subject of tandem vs single isotope approach.

**Primary author:** Prof. EZZIDDIN , Samer (Saarland University Hospital, Homburg)

**Presenter:** Prof. EZZIDDIN , Samer (Saarland University Hospital, Homburg)

**Session Classification:** Lessons learned from recent targeted radiotherapy treatments

**Track Classification:** Preclinical research and development of new radiopharmaceuticals